Stein M E, Kuten A, Drumea K, Moshkowitz B, Nativ C, Munichor M, Haim N
Northern Israel Oncology Center, Rambam Medical Center, Haifa, Israel.
J Surg Oncol. 1997 Apr;64(4):331-5. doi: 10.1002/(sici)1096-9098(199704)64:4<331::aid-jso15>3.0.co;2-5.
The efficacy of cisplatinum combined chemotherapy modalities was investigated in a variety of trials for patients with advanced seminoma. Results regarding remission rates and survival are encouraging.
Between December 1981 and January 1994, 13 patients with either relapsed (following radiotherapy failure) or primarily advanced seminoma were treated with cisplatin-based chemotherapy at the Northern Israel Oncology Center.
Eleven (84%) patients achieved complete clearance of all sites of disease. One patient demonstrated clinically and radiographically remarkable shrinkage of an abdominal mass, and laparotomy revealed fibrotic/necrotic tissue without viable tumor cells. After a mean follow-up of 58 months (range 4-168), 12 patients (92%) are alive and well without evidence of malignancy. One patient, in whom a 2-cm abdominal mass is stable radiographically, is under observation with no sign of tumor activity. Side effects were tolerable; no patient developed chemotherapy-induced sepsis. One patient developed spontaneous pneumothorax a few days after completion of his first chemotherapy cycle, which resolved with treatment.
Our results confirm the efficacy and safety of cisplatin-based chemotherapy in the treatment of advanced seminoma, even in pre-irradiated patients.
在多项针对晚期精原细胞瘤患者的试验中，研究了顺铂联合化疗方案的疗效。缓解率和生存率方面的结果令人鼓舞。
1981年12月至1994年1月期间，以色列北部肿瘤中心对13例复发（放疗失败后）或初治晚期精原细胞瘤患者采用了以顺铂为基础的化疗。
11例（84%）患者实现了所有病灶的完全清除。1例患者腹部肿块在临床和影像学上显著缩小，剖腹探查显示为纤维化/坏死组织，未见存活肿瘤细胞。平均随访58个月（4 - 168个月）后，12例（92%）患者存活且状况良好，无恶性肿瘤迹象。1例患者腹部有一个2厘米的肿块，影像学检查显示稳定，正在观察中，无肿瘤活动迹象。副作用可耐受；无患者发生化疗引起的败血症。1例患者在完成第一个化疗周期几天后发生自发性气胸，经治疗后痊愈。
我们的结果证实了以顺铂为基础的化疗在治疗晚期精原细胞瘤中的有效性和安全性，即使是对放疗前患者也是如此。
